The company develops and commercializes regenerative human tissues and organs for transplantation, focusing on bioengineered vascular grafts. Its lead product, the Human Acellular Vessel, is designed to address unmet needs in vascular trauma, dialysis access, and peripheral arterial disease. Investors track it for its potential in regenerative medicine and its pipeline of innovative therapies.
1 member of Congress has disclosed 9 trades in Humacyte, Inc. (HUMA), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 4 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2024-05-03 | Thomas H Tuberville | sell | $1K – $15K |
| 2024-05-03 | Thomas H Tuberville | sell | $15K – $50K |
| 2024-04-30 | Thomas H Tuberville | sell | $50K – $100K |
| 2024-03-21 | Thomas H Tuberville | buy | $1K – $15K |
| 2024-03-21 | Thomas H Tuberville | buy | $15K – $50K |
| 2024-02-12 | Thomas H Tuberville | buy | $15K – $50K |
| 2024-01-19 | Thomas H Tuberville | sell | $1K – $15K |
| 2023-07-25 | Thomas H Tuberville | buy | $1K – $15K |
| 2022-03-30 | Thomas H Tuberville | buy | $15K – $50K |